Drugs / L-Lactic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02539303 | Aug 2015 → Aug 2022 | peripheral arterial disease | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Lactic acid | “This is a feasibility pilot study to evaluate the impact of local delivery of Yamani-15/5 (combination of L-Lactic acid 15% and D-Gluconic acid 5%) on vascular calcification of...” NCT02539303 ↗ |
| Modality | Small molecule | — CHEMBL330546 ↗ |
| Route | Other | “A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.” NCT02539303 ↗ |